Sickle Cell Disease Clinical Trials in Chicago, Illinois

14 studies are recruiting for sickle cell disease in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Univer Of Illinois at Chicago, Chicago, Illinois

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Childrens Hospital of Chicago, Chicago, Illinois

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

   This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences System, Chicago, Illinois

   Locations

   9 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT07187973 on ClinicalTrials.gov

4. Tocilizumab for Acute Chest Syndrome

   The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with ch…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05640271 on ClinicalTrials.gov

5. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Uni of Illinois Hospital and HSC, Chicago, Illinois

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

6. A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

   The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Illinois at Chicago Clinical Research Center, Chicago, Illinois

   Locations

   80 in total

   Run by

   Pfizer

   See if you can join NCT05431088 on ClinicalTrials.gov

7. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

8. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study detai…

   Stage

   Phase 3

   Ages

   10 to 65

   Site

   University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago, Illinois

   Locations

   53 in total

   Run by

   Sanofi

   See if you can join NCT06975865 on ClinicalTrials.gov

9. Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

   The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary…

   Stage

   Phase 2

   Ages

   16 to 60

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT03121001 on ClinicalTrials.gov

10. Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

    In a hybrid type I effectiveness-implementation trial, our three-center research teams aim to examine whether empowering adults with sickle cell disease (SCD) with patient-facing SCD-specific guidelines through an mHealth application with booklets will decrease acute healthcare utilization and be c…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Locations

    4 in total

    Run by

    Ohio State University

    See if you can join NCT06919224 on ClinicalTrials.gov

11. Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

    This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate …

    Stage

    Phase 2

    Ages

    2 to 25

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    7 in total

    Run by

    Robert Nickel

    See if you can join NCT03587272 on ClinicalTrials.gov

12. Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

    The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also s…

    Stage

    Not phased

    Ages

    16 to 30

    Site

    Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    14 in total

    Run by

    University of Pittsburgh

    See if you can join NCT06374238 on ClinicalTrials.gov

13. Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

    The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Illinois, Chicago, Illinois

    Locations

    9 in total

    Run by

    RTI International

    See if you can join NCT06385886 on ClinicalTrials.gov

14. A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

    A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Illinois at Chicago College of Medicine, Chicago, Illinois

    Run by

    EpiDestiny, Inc.

    See if you can join NCT04055818 on ClinicalTrials.gov